Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)
- Conditions
- Vaso-occlusive CrisisSickle Cell Disease
- Registration Number
- NCT05376046
- Lead Sponsor
- BILLOIR
- Brief Summary
Sickle cell disease (SCD) is an inherited haemoglobinopathy disorder caused by mutations in HBB gene with amino-acid substitution on β globin chain. The consequence is synthesis of altered haemoglobin S (HbS) which polymerises in red blood cell (RBC) at deoxygenated state. SCD is associated with chronic haemolytic anaemia, vaso-occlusive crisis (VOC) leading to frequent hospitalisation.
The aim of the study was to to investigate whether a combination of routine laboratory biomarkers of haemolysis could be used to predict VOC development in confirmed SCD patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Sickle cell disease
- <18 years
- pregnancy
- Patient under protective guardianship or curatorship
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hospitalisation for Vaso-occlusive crisis within one years 1 year Following injury consultation, evaluation of biological markers predicting vaso-occlusive crisis requiring hospitalisation in the year
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Rouen university Hospital
🇫🇷Rouen, France
Rouen university Hospital🇫🇷Rouen, France